Nuclear medicine : Radiopharmaceuticals are radioactive compounds administered to the patient, and monitored via specific imaging devices, for diagnosis and therapeutic purposes. A Radiopharmaceutical is a drug that can be used either for diagnostic or therapeutic purposes.
The Radiopharmaceuticals in Nuclear Medicine market revenue was xx.xx Million USD in 2019, and will reach xx.xx Million USD in 2025, with a CAGR of x.x% during 2020-2025.
Under COVID-19 outbreak globally, this report provides 360 degrees of analysis from supply chain, import and export control to regional government policy and future influence on the industry. Detailed analysis about market status (2015-2020), enterprise competition pattern, advantages and disadvantages of enterprise products, industry development trends (2020-2025), regional industrial layout characteristics and macroeconomic policies, industrial policy has also been included. From raw materials to end users of this industry are analyzed scientifically, the trends of product circulation and sales channel will be presented as well. Considering COVID-19, this report provides comprehensive and in-depth analysis on how the epidemic push this industry transformation and reform.
In COVID-19 outbreak, Chapter 2.2 of this report provides an analysis of the impact of COVID-19 on the global economy and the Radiopharmaceuticals in Nuclear Medicine industry.
Chapter 3.7 covers the analysis of the impact of COVID-19 from the perspective of the industry chain.
In addition, chapters 7-11 consider the impact of COVID-19 on the regional economy.
The Radiopharmaceuticals in Nuclear Medicine market can be split based on product types, major applications, and important countries as follows:
Key players in the global Radiopharmaceuticals in Nuclear Medicine market covered in Chapter 12:
Siemens AG
Medtronic, Inc.
Lantheus Medical Imaging
IBA Group
Novartis International AG (Advanced accelerator)
Jubilant Life science
General Electric Co. (healthcare division)
Fujifilm Holding Corporation
Cardinal Health
Curium Pharma
Bayer AG
Lantheus Medical Imaging, Inc.
Mallinckrodt plc
Cardinal Health, Inc.
In Chapter 4 and 14.1, on the basis of types, the Radiopharmaceuticals in Nuclear Medicine market from 2015 to 2025 is primarily split into:
Diagnostic
Therapeutic
In Chapter 5 and 14.2, on the basis of applications, the Radiopharmaceuticals in Nuclear Medicine market from 2015 to 2025 covers:
Oncology
Cardiology
Neurology
Thyroid
Others
Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2025) of the following regions are covered in Chapter 6, 7, 8, 9, 10, 11, 14:
North America (Covered in Chapter 7 and 14)
United States
Canada
Mexico
Europe (Covered in Chapter 8 and 14)
Germany
UK
France
Italy
Spain
Russia
Others
Asia-Pacific (Covered in Chapter 9 and 14)
China
Japan
South Korea
Australia
India
Southeast Asia
Others
Middle East and Africa (Covered in Chapter 10 and 14)
Saudi Arabia
UAE
Egypt
Nigeria
South Africa
Others
South America (Covered in Chapter 11 and 14)
Brazil
Argentina
Columbia
Chile
Others
Years considered for this report:
Historical Years: 2015-2019
Base Year: 2019
Estimated Year: 2020
Forecast Period: 2020-2025
Summary:
Get latest Market Research Reports on Radiopharmaceuticals in Nuclear Medicine. Industry analysis & Market Report on Radiopharmaceuticals in Nuclear Medicine is a syndicated market report, published as COVID-19 Outbreak-Global Radiopharmaceuticals in Nuclear Medicine Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020. It is complete Research Study and Industry Analysis of Radiopharmaceuticals in Nuclear Medicine market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.